SITE007-0085

SITE007 (JPN) › SITE007-0085

SITE007-0085

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE007 (JPN) · Dr. Dubois
consented 2025-12-03

enrolled

AEs

6

Serious

0

Dropout signal

–

Adverse events

6

Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-11-11 (study day 149); relationship: RELATED

moderate assessed

Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-11-10 (study day 148); relationship: RELATED

severe assessed

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-10-23 (study day 130); relationship: not assessed

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-09-28 (study day 105); relationship: NOT RELATED

moderate assessed

Grade 3 Dyspnoea — outcome: UNKNOWN; onset 2022-09-18 (study day 95); relationship: NOT RELATED

severe assessed

Grade 3 Alanine aminotransferase increased — outcome: RECOVERED/RESOLVED; onset 2022-07-13 (study day 28); relationship: not assessed

severe assessed

Data queries

0

No data queries. Open queries would appear here for this patient.